Moleculin Biotech, Inc. (MBRX) Analysts See $-0.14 EPS

July 14, 2018 - By Jason Grubb

Analysts expect Moleculin Biotech, Inc. (NASDAQ:MBRX) to report $-0.14 EPS on August, 13.They anticipate $0.07 EPS change or 100.00 % from last quarter’s $-0.07 EPS. After having $-0.11 EPS previously, Moleculin Biotech, Inc.’s analysts see 27.27 % EPS growth. The stock increased 1.16% or $0.02 during the last trading session, reaching $1.74. About 74,934 shares traded. Moleculin Biotech, Inc. (NASDAQ:MBRX) has risen 88.76% since July 14, 2017 and is uptrending. It has outperformed by 76.19% the S&P500.

Moleculin Biotech, Inc., a preclinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. The company has market cap of $46.74 million. The Company’s lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. It currently has negative earnings. The firm also develops other drugs, including WP1066 Portfolio that focuses on the modulation of regulatory transcription factors involved in the progression of cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma.

More notable recent Moleculin Biotech, Inc. (NASDAQ:MBRX) news were published by: Investingnews.com which released: “Pharmaceutical Update: Q2 2018 in Review” on July 10, 2018, also Benzinga.com with their article: “56 Biggest Movers From Yesterday” published on June 22, 2018, Benzinga.com published: “Mid-Morning Market Update: Markets Mostly Higher; Winnebago Earnings Top Estimates” on June 20, 2018. More interesting news about Moleculin Biotech, Inc. (NASDAQ:MBRX) were released by: Benzinga.com and their article: “44 Stocks Moving In Thursday’s Mid-Day Session” published on June 21, 2018 as well as Benzinga.com‘s news article titled: “50 Biggest Movers From Yesterday” with publication date: June 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.